ARTICLE | Finance
Carmot deepens commitment to metabolic pipeline with $160M series D
Biotech believes dual modulator could be best in a class that includes Lilly’s Mounjaro
July 26, 2022 8:13 PM UTC
A new $160 million round will help Carmot drive three programs forward in the clinic, including one that could be first in class and another best in class to treat obesity and diabetes.
First-time backer RA Capital joined a series D syndicate led by returning investor The Column Group. Carmot Therapeutics Inc. has now raised more than $220 million since its inception, including a $47 million series C in 2020, according to BioCentury’s BCIQ database...